Vinpocetine ameliorates bone erosion and joint inflammation in rheumatoid arthritis via suppression of NLRP3 inflammasome
- 1College of Pharmacy, Chung-Ang University, Seoul, 06974 Republic of Korea
Abstract
Background: Rheumatoid arthritis (RA) is an autoimmune disease characterized by persistent synovial hyperplasia, cartilage degradation, and bone erosion. Vinpocetine (VIN), a semisynthetic derivative of the alkaloid vincamine, exhibits anti-inflammatory effects. However, the effect of VIN on NLRP3-mediated inflammation in RA remains unclear.
Results: In the collagen-induced arthritis (CIA) mouse model, treatment with vinpocetine (VIN) at doses of 5 and 10 mg/kg significantly alleviated characteristic symptoms of rheumatoid arthritis in CIA mice, including joint swelling, reduced grip strength, and mechanical hypersensitivity. Histopathological features of rheumatoid arthritis, such as bone erosion, cartilage destruction, and synovial hyperplasia, were also markedly improved in the CIA + VIN groups. In addition, the mRNA and protein expression levels of RA-associated inflammatory cytokines were significantly elevated in the CIA group but were markedly reduced in both CIA + VIN groups. Notably, VIN significantly suppressed the expression of NLRP3 inflammasome-related factors, including NLRP3, IL-1β, and IL-18, in CIA mice. Furthermore, VIN suppressed NLRP3 expression and inhibited osteoclastogenesis in bone marrow-derived macrophages (BMDMs).
Conclusion: This study demonstrates that VIN mitigates structural damage in vivo and reduces joint inflammation by suppressing NLRP3 inflammasome activation in both in vivo and in vitro models, supporting its potential as a therapeutic candidate for rheumatoid arthritis.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s13062-026-00991-1.
Related
- Macrophage lipid metabolism and inflammasome activation in rheumatoid arthritis: emerging mechanisms and therapeutic implications
- RNF130 ameliorates renal injury and inflammation by inhibiting macrophage pyroptosis through ubiquitination degradation of PDCD4 in male mice
- ROS-NLRP3 Inflammasome Axis in Obesity: A Critical Review of Oxidative Stress-Driven Inflammation and Emerging Therapeutic Strategies.
- Dihydromyricetin Ameliorates Exercise-Induced Acute Hepatic Dysfunction and Inflammation in Association with the Restoration of the Th17/Treg Balance in Mice
- Anti-Inflammatory Protein Hydrolysate Screened from Crayfish Shells Attenuates Colitis by Oxidative Stress Suppression, Inflammation Reduction and Barrier Reconstruction.
BibTeX
@article{lee2026vinpocetine,
title = {{Vinpocetine ameliorates bone erosion and joint inflammation in rheumatoid arthritis via suppression of NLRP3 inflammasome}},
author = {Yubin Lee and Hyeon Ho Gil and Hyeon Seong Jang and Jin Yong Song and Ji-Yun Lee},
journal = {Biology Direct},
year = {2026},
month = oct,
doi = {10.1186/s13062-026-00991-1},
url = {https://doi.org/10.1186/s13062-026-00991-1},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Vinpocetine ameliorates bone erosion and joint inflammation in rheumatoid arthritis via suppression of NLRP3 inflammasome
AU - Yubin Lee
AU - Hyeon Ho Gil
AU - Hyeon Seong Jang
AU - Jin Yong Song
AU - Ji-Yun Lee
PY - 2026
DA - 2026/10/02
JO - Biology Direct
DO - 10.1186/s13062-026-00991-1
UR - https://doi.org/10.1186/s13062-026-00991-1
AB - Background: Rheumatoid arthritis (RA) is an autoimmune disease characterized by persistent synovial hyperplasia, cartilage degradation, and bone erosion. Vinpocetine (VIN), a semisynthetic derivative of the alkaloid vincamine, exhibits anti-inflammatory effects. However, the effect of VIN on NLRP3-mediated inflammation in RA remains unclear. Results: In the collagen-induced arthritis (CIA) mouse model, treatment with vinpocetine (VIN) at doses of 5 and 10 mg/kg significantly alleviated characteristic symptoms of rheumatoid arthritis in CIA mice, including joint swelling, reduced grip strength, and mechanical hypersensitivity. Histopathological features of rheumatoid arthritis, such as bone erosion, cartilage destruction, and synovial hyperplasia, were also markedly improved in the CIA + VIN groups. In addition, the mRNA and protein expression levels of RA-associated inflammatory cytokines were significantly elevated in the CIA group but were markedly reduced in both CIA + VIN groups. Notably, VIN significantly suppressed the expression of NLRP3 inflammasome-related factors, including NLRP3, IL-1β, and IL-18, in CIA mice. Furthermore, VIN suppressed NLRP3 expression and inhibited osteoclastogenesis in bone marrow-derived macrophages (BMDMs). Conclusion: This study demonstrates that VIN mitigates structural damage in vivo and reduces joint inflammation by suppressing NLRP3 inflammasome activation in both in vivo and in vitro models, supporting its potential as a therapeutic candidate for rheumatoid arthritis. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s13062-026-00991-1.
SN - 1745-6150
ER -